Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.005	$ 0.005
Current assets:
Cash and cash equivalents	$ 152,183	$ 1,844,732
Short-term investments	178,391	134,603
Accounts receivable	201,297	216,183
Prepaid expenses	499,791	981,895
Contract asset	82,324	132,572
Other current assets	324,505	837,358
Total current assets	1,438,491	4,147,343
Non-current assets:
Operating lease right-of-use assets	1,126,828	964,331
Restricted cash	0	5,000,000
Goodwill	9,267,007	9,267,007
Intangible assets, net	1,467,271	1,580,980
Property and equipment, net	201,969	201,901
Total non-current assets	12,063,075	17,014,219
Assets of discontinued operation	8,123	8,123
Total assets	13,509,689	21,169,685
Current liabilities:
Accounts payable and accrued expenses	8,291,805	5,715,956
Current portion of operating lease liabilities	353,439	254,998
Deferred revenue	205,825	373,468
Stock issuances due	325,828	325,828
Notes payable	5,896,486	4,575,000
Total current liabilities	15,073,383	11,245,250
Operating lease liabilities, net of current portion	871,297	806,140
Long-term debt	0	10,625,000
Total long-term liabilities	871,297	11,431,140
Liabilities of discontinued operation	63	63
Total liabilities	15,944,743	22,676,453
Stockholders’ deficit:
Preferred stock, $.005 par value; 1,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021	0	0
Common stock, $.005 par value; 150,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 49,979,531 shares issued and outstanding as of March 31, 2022 and 35,484,106 shares issued and outstanding as of December 31, 2021	249,898	177,421
Additional paid-in capital	134,528,590	127,743,333
Accumulated other comprehensive loss	(24,252)	(6,651)
Accumulated deficit	(137,239,351)	(129,482,141)
Total Statera Biopharma, Inc. stockholders’ deficit	(2,485,115)	(1,568,038)
Noncontrolling interest in stockholders’ equity	50,061	61,270
Total stockholders’ deficit	(2,435,054)	(1,506,768)
Total liabilities and stockholders’ deficit	$ 13,509,689	$ 21,169,685